Enanta Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Monday, 06 January 2014 03:09
Jan. 6, 2014 13:30 UTC

Enanta Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Presentation to be Webcast on January 14, 2014 at 11:00 A.M. PT

JPMorgan Healthcare Conference 2014

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a presentation regarding the company on January 14, 2014, at 11:00 A.M. PT during the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. A question and answer session with investors will follow the presentation.

The presentation and the question and answer session will be webcast live and can be accessed by visiting the Investor homepage section of Enanta’s website at www.enanta.com. A replay of the presentation and question and answer session will be available following the sessions and

will be archived for approximately 60 days.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and

Error. Page cannot be displayed. Please contact your service provider for more details. (5)

drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and
oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.

Contacts

Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com


Source: Enanta Pharmaceuticals, Inc.




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BMR:1